AI assistant
Immunocore Holdings plc — Director's Dealing 2024
Jan 2, 2024
31805_dirs_2024-01-02_eede91a6-2c82-403e-ac9b-447e27d449d9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Immunocore Holdings plc (IMCR)
CIK: 0001671927
Period of Report: 2024-01-02
Reporting Person: Berman David M (Head of R&D)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Share Option (Right to Buy) | $17.46 | 2028-09-12 | Ordinary Shares (391790) | Direct | |
| Employee Share Option (Right to Buy) | $26.00 | 2031-02-03 | Ordinary Shares (468623) | Direct | |
| Employee Share Option (Right to Buy) | $24.66 | 2032-02-15 | Ordinary Shares (134271) | Direct | |
| Employee Share Option (Right to Buy) | $64.53 | 2033-02-15 | Ordinary Shares (90599) | Direct |
Footnotes
F1: Immediately exercisable.
F2: 25% of the shares subject to the option award vested on February 4, 2022, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F3: 25% of the shares subject to the option award vested on February 16, 2023, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F4: 25% of the shares subject to the option award shall vest on February 16, 2024, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.